anti-HER2 antibody-drug conjugate THIOMAB/Dolasynthen (Mersana Therapeutics/Genentech)

N/A

Report date: 2025/01/26 19:00:38

Base Information

Drug Nameanti-HER2 antibody-drug conjugate THIOMAB/Dolasynthen (Mersana Therapeutics/Genentech)
Drug Alias Nametrastuzumab-based ADC THIOMAB/Dolasynthen (Mersana Therapeutics/Genentech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMersana Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenetec IncMersana Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A